BioNTech SE Sponsored ADR $BNTX Stock Holdings Cut by Carmignac Gestion

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Carmignac Gestion reduced its position in BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 16.3% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 185,877 shares of the company's stock after selling 36,218 shares during the quarter. Carmignac Gestion owned approximately 0.08% of BioNTech worth $17,005,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Banque Cantonale Vaudoise acquired a new position in shares of BioNTech in the 1st quarter worth approximately $36,000. Costello Asset Management INC bought a new position in BioNTech during the first quarter worth $91,000. Goodman Advisory Group LLC acquired a new position in BioNTech in the first quarter worth $105,000. Tower Research Capital LLC TRC increased its stake in BioNTech by 61.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,881 shares of the company's stock valued at $214,000 after purchasing an additional 713 shares during the last quarter. Finally, Probity Advisors Inc. increased its stake in BioNTech by 8.5% during the fourth quarter. Probity Advisors Inc. now owns 1,970 shares of the company's stock valued at $224,000 after purchasing an additional 154 shares during the last quarter. Institutional investors own 15.52% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on BNTX. Bank of America raised their price target on shares of BioNTech from $126.00 to $134.00 and gave the stock a "buy" rating in a research report on Tuesday, August 5th. Wall Street Zen upgraded BioNTech from a "sell" rating to a "hold" rating in a research note on Saturday, June 7th. JPMorgan Chase & Co. lowered their target price on BioNTech from $120.00 to $116.00 and set a "neutral" rating for the company in a report on Thursday, May 22nd. Morgan Stanley raised their price target on BioNTech from $132.00 to $133.00 and gave the stock an "overweight" rating in a report on Thursday, July 10th. Finally, The Goldman Sachs Group initiated coverage on BioNTech in a research note on Thursday, May 29th. They set a "neutral" rating and a $110.00 price objective for the company. Thirteen analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $135.80.

BioNTech Stock Performance

BNTX stock traded up $0.11 on Friday, reaching $110.88. The company's stock had a trading volume of 401,202 shares, compared to its average volume of 701,675. The firm has a fifty day moving average of $109.90 and a two-hundred day moving average of $105.38. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.61 and a quick ratio of 8.48. The company has a market capitalization of $26.66 billion, a P/E ratio of -69.30 and a beta of 1.23. BioNTech SE Sponsored ADR has a 52 week low of $81.20 and a 52 week high of $131.49.

BioNTech (NASDAQ:BNTX - Get Free Report) last announced its quarterly earnings results on Monday, August 4th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.41) by ($0.19). The business had revenue of $306.46 million for the quarter, compared to analyst estimates of $161.26 million. BioNTech had a negative return on equity of 1.84% and a negative net margin of 12.20%.The company's revenue was up 102.6% compared to the same quarter last year. During the same quarter last year, the firm posted ($3.36) EPS. BioNTech has set its FY 2025 guidance at EPS. As a group, analysts predict that BioNTech SE Sponsored ADR will post -3.88 EPS for the current fiscal year.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.